What we do
We want to cure cancer that until now could not be cured!
18 million new cancer cases occur annually, and about 9 million deaths attributable to cancer are recorded each year, illustrating the magnitude of the impact of malignant tumors on human health.
Our cell therapy product pTTL – personalised Tumour Trained Lymphocytes – provides a unique immunotherapy with the aim to treat solid cancer without side effects. Preparations for the first clinical study in solid cancer is currently underway.
In pTTL our proprietary technologies, PIOR™ software and EpiTCer® are applied for identifying the most optimal neoantigens to target and to activate and multiply T-lymphocytes against the identified neoantigens with the purpose of eradicating the cancer.
EpiTCer® is a powerful technology that can also be utilised in other application areas such as vaccination and T-cell diagnostics.
Who we are
NEOGAP Therapeutics is a privately held biopharmaceutical company with the main focus on immuno-oncology. The company was founded in 2016 by Dr. Hans Grönlund and is located at Centre for Molecular Medicine at Karolinska Institutet, Stockholm, Sweden.
We are a multidisciplinary team with highly skilled and motivated individuals, bringing together an extensive experience and track record from academia and the pharmaceutical industry.
Our vision is to increase overall survival among patients with cancer by boosting tumour-specific responses of the immune system.
Our mission is to become an important player in the battle against cancer by development and commercialisation of our innovative cancer immunotherapy expected to act without side effects.